Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Rating of “Hold” by Brokerages

Soleno Therapeutics, Inc. (NASDAQ:SLNO) has earned an average rating of “Hold” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $76.6667.

A number of research firms have issued reports on SLNO. Lifesci Capital lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Robert W. Baird lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Wolfe Research lowered shares of Soleno Therapeutics from an “outperform” rating to a “hold” rating in a report on Tuesday, April 7th. Oppenheimer reduced their target price on shares of Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd.

Soleno Therapeutics Price Performance

Soleno Therapeutics stock opened at $52.95 on Tuesday. The firm has a market capitalization of $2.76 billion, a PE ratio of 230.23 and a beta of -2.22. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The firm’s 50-day simple moving average is $43.27 and its 200 day simple moving average is $46.35. Soleno Therapeutics has a 52 week low of $29.43 and a 52 week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The firm had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. On average, equities research analysts predict that Soleno Therapeutics will post 3.67 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in shares of Soleno Therapeutics during the 2nd quarter worth about $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics during the 3rd quarter worth about $27,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Soleno Therapeutics during the 3rd quarter worth about $37,000. Global Retirement Partners LLC lifted its holdings in shares of Soleno Therapeutics by 519.0% during the 4th quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock worth $29,000 after acquiring an additional 519 shares during the period. Finally, Quarry LP purchased a new position in shares of Soleno Therapeutics during the 3rd quarter worth about $47,000. Institutional investors and hedge funds own 97.42% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small?molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.